Steady and rapid advancement of clinical development
First written in FY2016. 19 of 21 entries say "Restated". Latest entry: FY2026-H1.
1 other company's latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The Group's policy is to select indications based on preclinical data and advance clinical development reliably and swiftly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly remains unchanged. - FY2025RestatedAnnual report
「The Group's policy is to select indications based on preclinical data and advance clinical development reliably and swiftly.」
The policy of selecting indications based on preclinical data and pursuing clinical development remains unchanged. - FY2024-Q3SoftenedAnnual report
「Plans for new clinical trials will be considered in light of the financial position.」
Regarding clinical development, the wording changed from uniformly advancing new clinical trials to a conditional statement that plans will be considered in light of the financial position. - FY2023-Q3RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly in Japan and overseas remains unchanged. - FY2023-Q1RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly in Japan and overseas remains unchanged. - FY2022-Q3RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly in Japan and overseas remains unchanged. - FY2022-Q1RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly in Japan and overseas remains unchanged. - FY2021-Q3RestatedAnnual report
「The Group's policy is to select indications based on preclinical data and advance clinical development reliably and swiftly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly in Japan and overseas remains unchanged. - FY2021-Q2RestatedAnnual report
「The Group's policy is to select indications based on preclinical data and advance clinical development reliably and swiftly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly in Japan and overseas remains unchanged. - FY2021-Q1RestatedAnnual report
「The Group's policy is to select indications based on preclinical data and advance clinical development reliably and swiftly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly in Japan and overseas remains unchanged. - FY2020-Q3RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on preclinical data and pursuing clinical development reliably and swiftly in Japan and overseas remains unchanged. - FY2020-Q2RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on nonclinical study data and advancing multiple clinical trials in Japan and overseas continues. - FY2020-Q1RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on nonclinical study data and advancing multiple clinical trials in Japan and overseas reliably and rapidly continues. - FY2018RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on nonclinical study data and advancing clinical development reliably and rapidly has been reiterated. - FY2018-Q3RestatedAnnual report
「Furthermore, in Japan and overseas, we are conducting multiple clinical trials jointly with partner pharmaceutical companies or independently as a group.」
Multiple clinical trials through joint development with partners and independent in-house development continue. - FY2018-Q2RestatedAnnual report
「Furthermore, in Japan and overseas, we are conducting multiple clinical trials jointly with partner pharmaceutical companies or independently as a group.」
Multiple clinical trials through joint development with partners and independent in-house development continue. - FY2017RestatedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy of selecting indications based on nonclinical study data and advancing clinical development reliably and rapidly has been reiterated. - FY2017-Q3RestatedAnnual report
「We are conducting multiple clinical trials based on the results of this drug discovery research and also have multiple drug candidates in preparation for clinical trials.」
The company continues to conduct multiple clinical trials and has multiple candidates in preparation. - FY2017-Q2RestatedAnnual report
「We are conducting multiple clinical trials based on the results of this drug discovery research and also have multiple drug candidates in preparation for clinical trials.」
The company has reiterated that it is conducting multiple clinical trials and has additional candidates in preparation. - FY2017-Q1RestatedAnnual report
「We are conducting multiple clinical trials based on the results of this drug discovery research and also have multiple drug candidates in preparation for clinical trials.」
Multiple clinical trials through both proprietary development and development with partners continue to be advanced. - FY2016First statedAnnual report
「Our Group plans to select indications based on preclinical data and advance clinical development steadily and rapidly.」
The policy is to advance multiple clinical trials through both in-house development and joint development with partners.